Thomas A. Glaze
Corporate Officer/Principal chez University of Washington
Profil
Thomas A.
Glaze is Chairman of Receptor BioLogix, Inc. and a Director of BayBio.
He is a Director and Founder of Essentialis and Limerick.
Mr. Glaze is a Member on the Advisory Boards of the Petit Institute for Bioengineering and Bioscience at Georgia Tech, and the Friday Harbor Labs of the University of Washington.
Previously, he founded Metabolex, Inc. and served as Chief Executive Officer.
He founded Monoclonal Antibodies, Inc. in 1979 and served as Chairman and Chief Executive Officer.
Mr. Glaze has over 25 years of experience in the biotechnology industry founding and managing companies in pharmaceuticals and medical devices.
He received an MBA and an MS degree from Stanford University and a BIE degree from the Georgia Institute of Technology.
Postes actifs de Thomas A. Glaze
| Sociétés | Poste | Début |
|---|---|---|
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Anciens postes connus de Thomas A. Glaze
| Sociétés | Poste | Fin |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | President | - |
The Georgia Tech Research Corp.
 The Georgia Tech Research Corp. Miscellaneous Commercial ServicesCommercial Services The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA. | Corporate Officer/Principal | - |
| The Bay Area Bioscience Association | Directeur/Membre du Conseil | - |
Limerick BioPharma, Inc.
 Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Fondateur | - |
Essentialis, Inc.
 Essentialis, Inc. Pharmaceuticals: OtherHealth Technology Essentialis, Inc. develops therapeutic products in curing metabolic diseases. It operates as a pharmaceutical company focusing on the development of breakthrough medicines for the treatment of rare metabolic diseases where there is mortality and risk of cardiovascular and endocrine complications. The company was founded by Neil M. Cowen, Jeffrey A. Staffa and Thomas A. Glaze in 2004 and is headquartered in San Diego, CA. | Fondateur | - |
Formation de Thomas A. Glaze
| Stanford University | Graduate Degree |
| Georgia Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Quidel Corp.
 Quidel Corp. Medical SpecialtiesHealth Technology Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA. | Health Technology |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
Essentialis, Inc.
Essentialis, Inc. Pharmaceuticals: OtherHealth Technology Essentialis, Inc. develops therapeutic products in curing metabolic diseases. It operates as a pharmaceutical company focusing on the development of breakthrough medicines for the treatment of rare metabolic diseases where there is mortality and risk of cardiovascular and endocrine complications. The company was founded by Neil M. Cowen, Jeffrey A. Staffa and Thomas A. Glaze in 2004 and is headquartered in San Diego, CA. | Health Technology |
Limerick BioPharma, Inc.
Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Health Technology |
| The Bay Area Bioscience Association | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
The Georgia Tech Research Corp.
The Georgia Tech Research Corp. Miscellaneous Commercial ServicesCommercial Services The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA. | Commercial Services |
